Optimizing axillary lymph node management in early-stage HR+/HER2- breast cancer: Practical strategies for enhanced detection rates

Dr. André Mattar

Abemaciclib is a globally approved, standard-of-care adjuvant treatment for HR+/HER2-high-risk EBC which significantly improved outcomes in combination with ET, versus ET alone, in the pivotal monarchE trial. Nodal involvement is a major adverse prognostic factor in EBC; however, clarity around methods and timepoints for evaluation of involved ALNs and identification of high-risk patients eligible for […]